Dexfenfluramine does not worsen but moderates progression of chronic hypoxia-induced pulmonary hypertension

European Journal of Pharmacology

Volumn 550, Issue 1-3, 2006, Pages 149-154

  Rochefort, Gaël Y ^a   Lemaire, Marie Christine ^a   Eder, Véronique ^a   Hanton, Gilles ^b   Hyvelin, Jean Marc ^a   Bonnet, Pierre ^a   Antier, Daniel ^a  

^a UNIVERSITÉ DE TOURS   (France)

^b PFIZER INC   (United States)

Author keywords

(Rat); Chronic hypoxia; Dexfenfluramine; Imaging; Pulmonary hypertension; Valvulopathy

Indexed keywords

DEXFENFLURAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HEART LEFT VENTRICLE MASS; HEART RIGHT VENTRICLE; HEART RIGHT VENTRICLE PRESSURE; HEART VENTRICLE SIZE; HEART VENTRICLE WALL; HEART WEIGHT; HEMODYNAMICS; HYPOXIA; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RAT;

ANIMALS; ANOXIA; BLOOD PRESSURE; BODY WEIGHT; CHRONIC DISEASE; DEXFENFLURAMINE; DISEASE PROGRESSION; FEMALE; HEART VALVE DISEASES; HYPERTENSION, PULMONARY; LUNG; MYOCARDIUM; ORGAN SIZE; RATS; RATS, WISTAR; SEROTONIN AGONISTS; SEROTONIN RECEPTOR AGONISTS; ULTRASONOGRAPHY, DOPPLER; VENTRICULAR FUNCTION, LEFT; VENTRICULAR FUNCTION, RIGHT; WEIGHT GAIN;

EID: 33749998142     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2006.08.050     Document Type: Article

References (16)

1. Abenhaim L., Moride Y., Brenot F., Rich S., Benichou J., Kurz X., Higenbottam T., Oakley C., Wouters E., Aubier M., Simonneau G., and Begaud B. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International primary pulmonary hypertension study group. N. Engl. J. Med. 335 (1996) 609-616
2. Blanpain C., Le Poul E., Parma J., Knoop C., Detheux M., Parmentier M., Vassart G., and Abramowicz M.J. Serotonin 5-HT(2B) receptor loss of function mutation in a patient with fenfluramine-associated primary pulmonary hypertension. Cardiovasc. Res. 60 (2003) 518-528
3. Bonnet P., Bonnet S., Boissiere J., Le Net J.L., Gautier M., Dumas de la Roque E., and Eder V. Chronic hypoxia induces nonreversible right ventricle dysfunction and dysplasia in rats. Am. J. Physiol., Heart Circ. Physiol. 287 (2004) H1023-H1028
4. Brindley D.N., and Russell J.C. Metabolic abnormalities linked to obesity: effects of dexfenfluramine in the corpulent rat. Metabolism 44 (1995) 23-27
5. Brindley D.N., Hales P., al-Sieni A.I., and Russell J.C. Sustained decreases in weight and serum insulin, glucose, triacylglycerol and cholesterol in JCR:LA-corpulent rats treated with d-fenfluramine. Br. J. Pharmacol. 105 (1992) 679-685
6. Eddahibi S., Raffestin B., Pham I., Launay J.M., Aegerter P., Sitbon M., and Adnot S. Treatment with 5-HT potentiates development of pulmonary hypertension in chronically hypoxic rats. Am. J. Physiol. 272 (1997) H1173-H1181
7. Eddahibi S., Hanoun N., Lanfumey L., Lesch K.P., Raffestin B., Hamon M., and Adnot S. Attenuated hypoxic pulmonary hypertension in mice lacking the 5-hydroxytryptamine transporter gene. J. Clin. Invest. 105 (2000) 1555-1562
8. Eddahibi S., Adnot S., Frisdal E., Levame M., Hamon M., and Raffestin B. Dexfenfluramine-associated changes in 5-hydroxytryptamine transporter expression and development of hypoxic pulmonary hypertension in rats. J. Pharmacol. Exp. Ther. 297 (2001) 148-154
9. Fitzgerald L.W., Burn T.C., Brown B.S., Patterson J.P., Corjay M.H., Valentine P.A., Sun J.H., Link J.R., Abbaszade I., Hollis J.M., Largent B.L., Hartig P.R., Hollis G.F., Meunier P.C., Robichaud A.J., and Robertson D.W. Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine. Mol. Pharmacol. 57 (2000) 75-81
10. Kato Y., Iwase M., Kanazawa H., Kawata N., Yoshimori Y., Hashimoto K., Yokoi T., Noda A., Takagi K., Koike Y., Nishizawa T., Nishimura M., and Yokota M. Progressive development of pulmonary hypertension leading to right ventricular hypertrophy assessed by echocardiography in rats. Exp. Anim. 52 (2003) 285-294
11. Launay J.M., Herve P., Peoc'h K., Tournois C., Callebert J., Nebigil C.G., Etienne N., Drouet L., Humbert M., Simonneau G., and Maroteaux L. Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension. Nat. Med. 8 (2002) 1129-1135
12. Loke Y.K., Derry S., and Pritchard-Copley A. Appetite suppressants and valvular heart disease - a systematic review. BMC Clin. Pharmacol. 2 (2002) 6
13. Marcos E., Adnot S., Pham M.H., Nosjean A., Raffestin B., Hamon M., and Eddahibi S. Serotonin transporter inhibitors protect against hypoxic pulmonary hypertension. Am. J. Respir. Crit. Care Med. 168 (2003) 487-493
14. Mitani Y., Mutlu A., Russell J.C., Brindley D.N., DeAlmeida J., and Rabinovitch M. Dexfenfluramine protects against pulmonary hypertension in rats. J. Appl. Physiol. 93 (2002) 1770-1778
15. Rabinovitch M., Gamble W.J., Miettinen O.S., and Reid L. Age and sex influence on pulmonary hypertension of chronic hypoxia and on recovery. Am. J. Physiol. 240 (1981) H62-H72
16. Rothman R.B., Baumann M.H., Savage J.E., Rauser L., McBride A., Hufeisen S.J., and Roth B.L. Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 102 (2000) 2836-2841